<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Fexofenadine - Complete Drug Monograph</title>
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/css/bootstrap.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css" rel="stylesheet">
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/gsap/3.12.2/gsap.min.js"></script>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            padding: 15px;
            line-height: 1.7;
        }

        .main-container {
            max-width: 1400px;
            margin: 0 auto;
            background: #f8f9fa;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }

        .header {
            background: linear-gradient(135deg, #1e3c72 0%, #2a5298 100%);
            color: white;
            padding: 40px 30px;
            text-align: center;
            position: relative;
            overflow: hidden;
        }

        .header::before {
            content: '';
            position: absolute;
            top: -50%;
            left: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 1px, transparent 1px);
            background-size: 50px 50px;
            animation: moveBackground 20s linear infinite;
        }

        @keyframes moveBackground {
            0% { transform: translate(0, 0); }
            100% { transform: translate(50px, 50px); }
        }

        .header h1 {
            font-size: 3rem;
            font-weight: 800;
            margin-bottom: 10px;
            position: relative;
            z-index: 1;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.3);
        }

        .header p {
            font-size: 1.3rem;
            position: relative;
            z-index: 1;
            opacity: 0.95;
        }

        .quick-nav {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            padding: 25px;
            margin: 20px;
            border-radius: 15px;
            box-shadow: 0 10px 30px rgba(0,0,0,0.2);
        }

        .quick-nav h2 {
            color: white;
            font-size: 1.8rem;
            margin-bottom: 20px;
            text-align: center;
            font-weight: 700;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.2);
        }

        .nav-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(280px, 1fr));
            gap: 12px;
        }

        .nav-item {
            background: rgba(255,255,255,0.95);
            padding: 12px 18px;
            border-radius: 10px;
            text-decoration: none;
            color: #2d3748;
            font-weight: 600;
            transition: all 0.3s ease;
            display: block;
            border-left: 4px solid #f5576c;
            font-size: 0.95rem;
        }

        .nav-item:hover {
            transform: translateX(8px);
            background: white;
            box-shadow: 0 5px 15px rgba(0,0,0,0.2);
            color: #f5576c;
        }

        .content-wrapper {
            padding: 30px;
        }

        .section {
            margin-bottom: 40px;
            background: white;
            border-radius: 15px;
            padding: 30px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.08);
            transition: transform 0.3s ease;
        }

        .section:hover {
            transform: translateY(-5px);
            box-shadow: 0 8px 30px rgba(0,0,0,0.12);
        }

        .section h2 {
            font-size: 2rem;
            margin-bottom: 20px;
            font-weight: 700;
            position: relative;
            padding-bottom: 15px;
        }

        .section h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 80px;
            height: 4px;
            border-radius: 2px;
        }

        .safety-section {
            background: linear-gradient(135deg, #ff6b6b 0%, #ee5a6f 100%);
            color: white;
        }

        .safety-section h2::after {
            background: white;
        }

        .identification-section {
            background: linear-gradient(135deg, #4facfe 0%, #00f2fe 100%);
            color: #1a202c;
        }

        .identification-section h2::after {
            background: #1e3c72;
        }

        .landscape-section {
            background: linear-gradient(135deg, #43e97b 0%, #38f9d7 100%);
            color: #1a202c;
        }

        .landscape-section h2::after {
            background: #0f5132;
        }

        .therapeutic-section {
            background: linear-gradient(135deg, #fa709a 0%, #fee140 100%);
            color: #1a202c;
        }

        .therapeutic-section h2::after {
            background: #c92a2a;
        }

        .administration-section {
            background: linear-gradient(135deg, #30cfd0 0%, #330867 100%);
            color: white;
        }

        .administration-section h2::after {
            background: #30cfd0;
        }

        .dosing-section {
            background: linear-gradient(135deg, #a8edea 0%, #fed6e3 100%);
            color: #1a202c;
        }

        .dosing-section h2::after {
            background: #e91e63;
        }

        .pharmacology-section {
            background: linear-gradient(135deg, #ff9a9e 0%, #fecfef 100%);
            color: #1a202c;
        }

        .pharmacology-section h2::after {
            background: #d63031;
        }

        .interaction-section {
            background: linear-gradient(135deg, #ffecd2 0%, #fcb69f 100%);
            color: #1a202c;
        }

        .interaction-section h2::after {
            background: #ff6348;
        }

        .adverse-section {
            background: linear-gradient(135deg, #ff6b95 0%, #ffc796 100%);
            color: #1a202c;
        }

        .adverse-section h2::after {
            background: #e74c3c;
        }

        .monitoring-section {
            background: linear-gradient(135deg, #a1c4fd 0%, #c2e9fb 100%);
            color: #1a202c;
        }

        .monitoring-section h2::after {
            background: #3498db;
        }

        .reproductive-section {
            background: linear-gradient(135deg, #fbc2eb 0%, #a6c1ee 100%);
            color: #1a202c;
        }

        .reproductive-section h2::after {
            background: #8e44ad;
        }

        .longterm-section {
            background: linear-gradient(135deg, #fddb92 0%, #d1fdff 100%);
            color: #1a202c;
        }

        .longterm-section h2::after {
            background: #f39c12;
        }

        .future-section {
            background: linear-gradient(135deg, #89f7fe 0%, #66a6ff 100%);
            color: #1a202c;
        }

        .future-section h2::after {
            background: #0984e3;
        }

        .myth-section {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border: 3px solid #f5576c;
        }

        .myth-section h2::after {
            background: #f5576c;
        }

        .info-box {
            background: rgba(255,255,255,0.1);
            padding: 20px;
            border-radius: 10px;
            margin: 15px 0;
            border-left: 5px solid rgba(255,255,255,0.5);
        }

        .warning-box {
            background: rgba(255,255,255,0.15);
            padding: 25px;
            border-radius: 12px;
            margin: 20px 0;
            border: 2px solid rgba(255,255,255,0.3);
            font-weight: 600;
        }

        .data-table {
            width: 100%;
            margin: 20px 0;
            border-collapse: separate;
            border-spacing: 0;
            border-radius: 10px;
            overflow: hidden;
            box-shadow: 0 4px 15px rgba(0,0,0,0.1);
        }

        .data-table th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 15px;
            text-align: left;
            font-weight: 700;
            font-size: 1.05rem;
        }

        .data-table td {
            padding: 12px 15px;
            border-bottom: 1px solid rgba(0,0,0,0.05);
            color: #2d3748;
            background: rgba(255,255,255,0.5);
        }

        .data-table tr:last-child td {
            border-bottom: none;
        }

        .data-table tr:hover td {
            background: rgba(102,126,234,0.1);
        }

        .icon-badge {
            display: inline-block;
            width: 40px;
            height: 40px;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            border-radius: 50%;
            text-align: center;
            line-height: 40px;
            color: white;
            margin-right: 10px;
            font-size: 1.2rem;
        }

        .list-item {
            padding: 12px 20px;
            margin: 10px 0;
            background: rgba(102,126,234,0.05);
            border-radius: 8px;
            border-left: 4px solid #667eea;
            transition: all 0.3s ease;
        }

        .list-item:hover {
            background: rgba(102,126,234,0.15);
            transform: translateX(5px);
        }

        .chart-container {
            position: relative;
            height: 400px;
            margin: 30px 0;
            background: white;
            padding: 20px;
            border-radius: 10px;
            box-shadow: 0 4px 15px rgba(0,0,0,0.08);
        }

        .timeline {
            position: relative;
            padding: 20px 0;
        }

        .timeline-item {
            padding: 20px;
            background: rgba(255,255,255,0.1);
            border-radius: 10px;
            margin: 15px 0;
            border-left: 5px solid rgba(255,255,255,0.5);
            transition: all 0.3s ease;
        }

        .timeline-item:hover {
            transform: translateX(10px);
            background: rgba(255,255,255,0.2);
        }

        .badge-custom {
            display: inline-block;
            padding: 6px 15px;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 600;
            margin: 5px;
        }

        .myth-icon {
            font-size: 3rem;
            margin-bottom: 20px;
            display: block;
            text-align: center;
        }

        .truth-box {
            background: rgba(255,255,255,0.15);
            padding: 25px;
            border-radius: 12px;
            margin-top: 20px;
            border: 2px dashed rgba(255,255,255,0.5);
        }

        @media (max-width: 768px) {
            body {
                padding: 8px;
            }

            .header h1 {
                font-size: 1.8rem;
            }

            .header p {
                font-size: 1rem;
            }

            .section {
                padding: 18px;
                margin-bottom: 25px;
            }

            .section h2 {
                font-size: 1.4rem;
            }

            .quick-nav {
                padding: 15px;
                margin: 15px 10px;
            }

            .quick-nav h2 {
                font-size: 1.3rem;
            }

            .nav-grid {
                grid-template-columns: 1fr;
                gap: 8px;
            }

            .nav-item {
                padding: 10px 14px;
                font-size: 0.85rem;
            }

            .content-wrapper {
                padding: 15px;
            }

            .data-table {
                font-size: 0.85rem;
            }

            .data-table th,
            .data-table td {
                padding: 8px 10px;
            }

            .chart-container {
                height: 300px;
                padding: 15px;
            }

            .info-box,
            .warning-box {
                padding: 15px;
                font-size: 0.9rem;
            }

            .list-item {
                padding: 10px 15px;
                font-size: 0.9rem;
            }

            .icon-badge {
                width: 32px;
                height: 32px;
                line-height: 32px;
                font-size: 1rem;
            }
        }
    </style>
</head>
<body>
    <div class="main-container">
        <div class="header">
            <h1><i class="fas fa-pills"></i> FEXOFENADINE</h1>
            <p>Second-Generation H1 Antihistamine - Complete Drug Monograph</p>
        </div>

        <div class="quick-nav">
            <h2><i class="fas fa-compass"></i> Quick Navigation</h2>
            <div class="nav-grid">
                <a href="#safety" class="nav-item">üö® Critical Safety Information</a>
                <a href="#history" class="nav-item">üìú History and Nomenclature</a>
                <a href="#classification" class="nav-item">üè∑Ô∏è Drug Classification</a>
                <a href="#news" class="nav-item">üì∞ Latest News & Guidelines</a>
                <a href="#indications" class="nav-item">üíä Clinical Indications</a>
                <a href="#age-usage" class="nav-item">üë®‚Äçüë©‚Äçüëß‚Äçüë¶ Age-Specific Usage</a>
                <a href="#administration" class="nav-item">üíâ Administration Guidelines</a>
                <a href="#dosing" class="nav-item">‚öñÔ∏è Dosing Parameters</a>
                <a href="#missed-dose" class="nav-item">‚è∞ Missed Dose Management</a>
                <a href="#conversion" class="nav-item">üîÑ Drug Conversion</a>
                <a href="#efficacy" class="nav-item">üìä Clinical Efficacy Data</a>
                <a href="#mechanism" class="nav-item">üß¨ Mechanism of Action</a>
                <a href="#contraindications" class="nav-item">‚õî Contraindications</a>
                <a href="#interactions" class="nav-item">‚ö†Ô∏è Drug Interactions</a>
                <a href="#adverse" class="nav-item">üò∑ Adverse Effects</a>
                <a href="#concerns" class="nav-item">üí¨ Patient Concerns</a>
                <a href="#cases" class="nav-item">üìã Case Reports</a>
                <a href="#pregnancy-pre" class="nav-item">ü§∞ Pregnancy Considerations</a>
                <a href="#lactation" class="nav-item">ü§± Lactation & Breastfeeding</a>
                <a href="#monitoring" class="nav-item">üî¨ Safety Monitoring</a>
                <a href="#storage" class="nav-item">üì¶ Storage & Handling</a>
                <a href="#longterm" class="nav-item">‚è≥ Long-term Effects</a>
                <a href="#nutrition" class="nav-item">ü•ó Nutritional Support</a>
                <a href="#management" class="nav-item">ü©∫ Side Effect Management</a>
                <a href="#dermatology" class="nav-item">üß¥ Dermatological Effects</a>
                <a href="#pregnancy-long" class="nav-item">ü§∞ Pregnancy Long-term</a>
                <a href="#laboratory" class="nav-item">üß™ Laboratory Monitoring</a>
                <a href="#future" class="nav-item">üîÆ Future Developments</a>
                <a href="#myths" class="nav-item">üîç Myths & Facts</a>
            </div>
        </div>

        <div class="content-wrapper">
            <section id="safety" class="section safety-section">
                <h2><i class="fas fa-exclamation-triangle"></i> Critical Safety Information</h2>
                <div class="warning-box">
                    <strong><i class="fas fa-info-circle"></i> Important Safety Notice:</strong> Fexofenadine has no FDA Black Box Warning. It is considered one of the safest antihistamines with minimal side effects and no significant cardiac toxicity.
                </div>
                <div class="info-box">
                    <h4><i class="fas fa-shield-alt"></i> Primary Safety Alerts</h4>
                    <p><strong>Hypersensitivity Reactions:</strong> Rare cases of anaphylaxis, angioedema, and bronchospasm have been reported post-marketing. Patients with known hypersensitivity to fexofenadine or any component should avoid use.</p>
                    <p><strong>Fruit Juice Interaction:</strong> Avoid taking fexofenadine with apple, orange, or grapefruit juice as they significantly reduce drug absorption and effectiveness.</p>
                    <p><strong>Renal Impairment:</strong> Dose adjustment required for patients with decreased kidney function.</p>
                </div>
                <div class="info-box">
                    <h4><i class="fas fa-heartbeat"></i> Risk Mitigation Strategies</h4>
                    <p>‚úì Take medication with water only, not fruit juices</p>
                    <p>‚úì Monitor for allergic reactions during first use</p>
                    <p>‚úì Adjust dosing in renal impairment patients</p>
                    <p>‚úì Avoid in patients with known hypersensitivity to antihistamines</p>
                </div>
            </section>

            <section id="history" class="section identification-section">
                <h2><i class="fas fa-history"></i> History and Nomenclature</h2>
                <div class="info-box">
                    <p><strong>Origin of Name:</strong> Fexofenadine is derived from its chemical structure and was developed as a metabolite of terfenadine.</p>
                    <p><strong>Brand Names:</strong> Allegra (United States), Telfast (International), Fastofen, Altiva, Tilfur, Fexo</p>
                    <p><strong>Chemical Name:</strong> (¬±)-4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-Œ±,Œ±-dimethyl benzeneacetic acid</p>
                </div>
                <div class="timeline">
                    <div class="timeline-item">
                        <strong>1996</strong> - Fexofenadine was discovered as the active metabolite of terfenadine, which was associated with cardiac arrhythmias
                    </div>
                    <div class="timeline-item">
                        <strong>2000</strong> - FDA approved fexofenadine for seasonal allergic rhinitis in adults and children
                    </div>
                    <div class="timeline-item">
                        <strong>2002</strong> - Approved for chronic idiopathic urticaria treatment
                    </div>
                    <div class="timeline-item">
                        <strong>2011</strong> - Became available over-the-counter (OTC) in the United States
                    </div>
                    <div class="timeline-item">
                        <strong>2024</strong> - FDA updated guidance on fexofenadine hydrochloride formulations
                    </div>
                </div>
            </section>

            <section id="classification" class="section landscape-section">
                <h2><i class="fas fa-sitemap"></i> Drug Classification and Category</h2>
                <div class="info-box">
                    <h4><i class="fas fa-tags"></i> Therapeutic Classification</h4>
                    <p><strong>Primary Class:</strong> Second-Generation Antihistamine</p>
                    <p><strong>Pharmacological Category:</strong> H1 Receptor Antagonist (Selective Peripheral)</p>
                    <p><strong>ATC Code:</strong> R06AX26</p>
                    <p><strong>DEA Schedule:</strong> Not a controlled substance</p>
                </div>

                <h4 style="margin-top: 25px; color: #1a202c;"><i class="fas fa-layer-group"></i> Drug Forms & Types</h4>
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Form</th>
                            <th>Strengths</th>
                            <th>Route</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Fexofenadine HCl Tablets</strong></td>
                            <td>30 mg, 60 mg, 120 mg, 180 mg</td>
                            <td>Oral</td>
                        </tr>
                        <tr>
                            <td><strong>Fexofenadine HCl Oral Suspension</strong></td>
                            <td>30 mg/5 mL, 6 mg/mL</td>
                            <td>Oral</td>
                        </tr>
                        <tr>
                            <td><strong>Fexofenadine HCl Orally Disintegrating Tablets (ODT)</strong></td>
                            <td>30 mg</td>
                            <td>Oral</td>
                        </tr>
                        <tr>
                            <td><strong>Combination: Fexofenadine + Pseudoephedrine</strong></td>
                            <td>60 mg/120 mg, 180 mg/240 mg</td>
                            <td>Oral</td>
                        </tr>
                    </tbody>
                </table>

                <h4 style="margin-top: 25px; color: #1a202c;"><i class="fas fa-pills"></i> Related Medications in H1-Antihistamine Class</h4>
                <div class="list-item">
                    <strong>Cetirizine:</strong> Second-generation antihistamine with slight sedating effects; used for allergic rhinitis and urticaria
                </div>
                <div class="list-item">
                    <strong>Loratadine:</strong> Non-sedating second-generation antihistamine; similar indications to fexofenadine
                </div>
                <div class="list-item">
                    <strong>Desloratadine:</strong> Active metabolite of loratadine; longer duration of action
                </div>
                <div class="list-item">
                    <strong>Levocetirizine:</strong> R-enantiomer of cetirizine; improved H1 selectivity
                </div>
                <div class="list-item">
                    <strong>Bilastine:</strong> Newer second-generation antihistamine with no sedation and no cardiac effects
                </div>
            </section>

            <section id="news" class="section therapeutic-section">
                <h2><i class="fas fa-newspaper"></i> Latest News and Guidelines Updates</h2>
                <div class="info-box">
                    <h4><i class="fas fa-calendar-alt"></i> Recent FDA Updates - 2024</h4>
                    <p><strong>October 2024:</strong> FDA published revised draft guidance on Fexofenadine Hydrochloride, updating bioequivalence recommendations and quality standards for generic formulations.</p>
                </div>
                <div class="info-box">
                    <h4><i class="fas fa-flask"></i> Clinical Research Updates</h4>
                    <p><strong>2024-2025:</strong> Clinical trial investigating fexofenadine as adjuvant therapy in Parkinson's Disease initiated. The study explores potential neuroprotective effects beyond traditional antihistamine action.</p>
                </div>
                <div class="info-box">
                    <h4><i class="fas fa-book-medical"></i> Professional Guidelines</h4>
                    <p><strong>American Academy of Allergy, Asthma & Immunology (AAAAI):</strong> Recommends second-generation antihistamines like fexofenadine as first-line therapy for allergic rhinitis due to superior safety profile.</p>
                    <p><strong>World Allergy Organization (WAO):</strong> Updated 2024 guidelines continue to recommend fexofenadine for chronic spontaneous urticaria with possible dose escalation up to 4 times the standard dose.</p>
                </div>
            </section>

            <section id="indications" class="section administration-section">
                <h2><i class="fas fa-stethoscope"></i> Clinical Indications</h2>
                <div class="info-box">
                    <h4><i class="fas fa-check-circle"></i> FDA-Approved Indications</h4>
                    <p><strong>1. Seasonal Allergic Rhinitis (Hay Fever):</strong></p>
                    <p>Relief of symptoms including sneezing, rhinorrhea, itchy nose/throat/palate, and itchy/watery/red eyes in patients ‚â•2 years of age.</p>
                    
                    <p><strong>2. Chronic Idiopathic Urticaria:</strong></p>
                    <p>Treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in patients ‚â•6 months of age. Reduces pruritus and number of wheals.</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-flask"></i> Off-Label Therapeutic Uses</h4>
                    <p><strong>‚Ä¢ Perennial Allergic Rhinitis:</strong> Effective for year-round allergic symptoms</p>
                    <p><strong>‚Ä¢ Atopic Dermatitis:</strong> Used as adjunctive therapy to reduce itching</p>
                    <p><strong>‚Ä¢ Contact Dermatitis:</strong> May help manage allergic skin reactions</p>
                    <p><strong>‚Ä¢ Physical Urticaria:</strong> Including cold urticaria and dermatographism</p>
                    <p><strong>‚Ä¢ Mastocytosis:</strong> Helps control histamine-mediated symptoms</p>
                </div>

                <div class="warning-box">
                    <h4><i class="fas fa-ban"></i> Contraindicated Conditions</h4>
                    <p>‚ùå Known hypersensitivity to fexofenadine or any component</p>
                    <p>‚ùå End-stage renal disease without dose adjustment</p>
                    <p>‚ùå Combination products contraindicated in severe hypertension, coronary artery disease, and MAO inhibitor use</p>
                </div>
            </section>

            <section id="age-usage" class="section dosing-section">
                <h2><i class="fas fa-users"></i> Age-Specific Usage Guidelines</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Age Group</th>
                            <th>Indication</th>
                            <th>Dosing</th>
                            <th>Notes</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Infants (6-24 months)</strong></td>
                            <td>Chronic Urticaria</td>
                            <td>15 mg twice daily (oral suspension)</td>
                            <td>Not approved for rhinitis</td>
                        </tr>
                        <tr>
                            <td><strong>Children (2-11 years)</strong></td>
                            <td>Both indications</td>
                            <td>30 mg twice daily</td>
                            <td>Oral suspension or tablets</td>
                        </tr>
                        <tr>
                            <td><strong>Adolescents (12+ years)</strong></td>
                            <td>Both indications</td>
                            <td>60 mg BID or 180 mg once daily</td>
                            <td>Adult dosing applies</td>
                        </tr>
                        <tr>
                            <td><strong>Adults (18-65 years)</strong></td>
                            <td>Both indications</td>
                            <td>60 mg BID or 180 mg once daily</td>
                            <td>Standard dosing</td>
                        </tr>
                        <tr>
                            <td><strong>Geriatric (>65 years)</strong></td>
                            <td>Both indications</td>
                            <td>Same as adults</td>
                            <td>Monitor renal function; consider 30-60 mg once daily if impairment present</td>
                        </tr>
                    </tbody>
                </table>

                <div class="info-box" style="margin-top: 25px;">
                    <h4><i class="fas fa-info-circle"></i> Why Certain Age Groups Are Excluded</h4>
                    <p><strong>Infants <6 months:</strong> Limited safety and efficacy data; immature hepatic and renal systems may affect drug clearance and increase risk of adverse effects.</p>
                    <p><strong>Infants 6-24 months for Rhinitis:</strong> Diagnosis of seasonal allergic rhinitis difficult in this age group; symptoms often confused with viral infections.</p>
                </div>
            </section>

            <section id="administration" class="section pharmacology-section">
                <h2><i class="fas fa-syringe"></i> Drug Administration Guidelines</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-route"></i> Routes of Administration</h4>
                    <p><strong>Oral Route Only:</strong> Fexofenadine is administered exclusively by mouth via tablets, oral suspension, or orally disintegrating tablets.</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-list-ol"></i> Step-by-Step Administration</h4>
                    <p><strong>For Tablets:</strong></p>
                    <p>1. Take tablet with a full glass of plain water</p>
                    <p>2. Swallow whole; do not crush, chew, or split</p>
                    <p>3. Can be taken with or without food (except ODT)</p>
                    <p>4. Do not take with fruit juices</p>
                    
                    <p style="margin-top: 15px;"><strong>For Oral Suspension:</strong></p>
                    <p>1. Shake bottle well before each use</p>
                    <p>2. Measure dose with calibrated measuring device</p>
                    <p>3. Administer directly or mix with small amount of water</p>
                    <p>4. Take on empty stomach if possible</p>
                    
                    <p style="margin-top: 15px;"><strong>For Orally Disintegrating Tablets (ODT):</strong></p>
                    <p>1. Take on an empty stomach (at least 1 hour before or 2 hours after food)</p>
                    <p>2. Remove from blister pack with dry hands</p>
                    <p>3. Place on tongue immediately; will disintegrate within seconds</p>
                    <p>4. Swallow with or without water</p>
                </div>

                <div class="warning-box">
                    <h4><i class="fas fa-apple-alt"></i> Food & Timing Interactions</h4>
                    <p><strong>AVOID Fruit Juices:</strong> Apple, orange, and grapefruit juice reduce fexofenadine absorption by up to 60-70%. Take with water only.</p>
                    <p><strong>Food Effects:</strong> Regular tablets can be taken with or without food. ODT formulations must be taken on empty stomach for optimal absorption.</p>
                    <p><strong>Optimal Timing:</strong> Taking medication at the same time daily maintains consistent blood levels and maximizes symptom control.</p>
                </div>
            </section>

            <section id="dosing" class="section interaction-section">
                <h2><i class="fas fa-balance-scale"></i> Dosing Parameters</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-clock"></i> Maximum Treatment Duration</h4>
                    <p><strong>Seasonal Allergic Rhinitis:</strong> Can be used throughout allergy season (weeks to months) as needed for symptom control.</p>
                    <p><strong>Chronic Urticaria:</strong> Long-term use (months to years) is safe and well-tolerated for chronic conditions.</p>
                    <p><strong>No Maximum Duration:</strong> Fexofenadine does not have a specified maximum treatment duration due to excellent long-term safety profile.</p>
                </div>

                <div class="warning-box">
                    <h4><i class="fas fa-exclamation-circle"></i> Maximum Daily Dose Restrictions</h4>
                    <p><strong>Standard Maximum:</strong> 180 mg per day for adults (single dose)</p>
                    <p><strong>Alternative Regimen:</strong> 60 mg twice daily (total 120 mg/day)</p>
                    <p><strong>Special Circumstances:</strong> In refractory chronic urticaria, doses up to 4x standard (720 mg/day) have been studied but require physician supervision</p>
                    <p><strong>Pediatric Maximum:</strong> 30 mg twice daily (60 mg total) for children 2-11 years</p>
                </div>

                <div class="chart-container">
                    <canvas id="dosingChart"></canvas>
                </div>
            </section>

            <section id="missed-dose" class="section adverse-section">
                <h2><i class="fas fa-clock"></i> Missed Dose Management</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-question-circle"></i> Decision-Making Algorithm</h4>
                    
                    <p><strong>Scenario 1: Once-Daily Dosing (180 mg)</strong></p>
                    <p>‚Ä¢ If you remember within 12 hours of missed dose ‚Üí Take immediately</p>
                    <p>‚Ä¢ If >12 hours have passed ‚Üí Skip missed dose, resume next scheduled dose</p>
                    <p>‚Ä¢ Never double the dose to catch up</p>
                    
                    <p style="margin-top: 15px;"><strong>Scenario 2: Twice-Daily Dosing (60 mg BID)</strong></p>
                    <p>‚Ä¢ If you remember within 4 hours of missed dose ‚Üí Take immediately</p>
                    <p>‚Ä¢ If >4 hours have passed ‚Üí Skip missed dose, take next scheduled dose</p>
                    <p>‚Ä¢ Maintain at least 8-hour interval between doses</p>
                    
                    <p style="margin-top: 15px;"><strong>Scenario 3: Multiple Consecutive Missed Doses</strong></p>
                    <p>‚Ä¢ Resume regular schedule with single dose</p>
                    <p>‚Ä¢ Do not take extra doses to compensate</p>
                    <p>‚Ä¢ Symptom control may take 1-2 days to restore</p>
                </div>

                <div class="warning-box">
                    <h4><i class="fas fa-shield-alt"></i> Recovery Protocols</h4>
                    <p>‚úì Return to regular dosing schedule as soon as possible</p>
                    <p>‚úì Set phone reminders to prevent future missed doses</p>
                    <p>‚úì Take medication at same time daily for consistency</p>
                    <p>‚úì Contact healthcare provider if missing doses frequently</p>
                </div>
            </section>

            <section id="conversion" class="section monitoring-section">
                <h2><i class="fas fa-exchange-alt"></i> Drug Conversion and Equivalency</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-equals"></i> Antihistamine Equivalency Guide</h4>
                    <p>When switching between second-generation H1-antihistamines for similar efficacy:</p>
                </div>

                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Drug</th>
                            <th>Equivalent Daily Dose</th>
                            <th>Dosing Frequency</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Fexofenadine</strong></td>
                            <td>120-180 mg</td>
                            <td>Once or twice daily</td>
                        </tr>
                        <tr>
                            <td><strong>Cetirizine</strong></td>
                            <td>10 mg</td>
                            <td>Once daily</td>
                        </tr>
                        <tr>
                            <td><strong>Loratadine</strong></td>
                            <td>10 mg</td>
                            <td>Once daily</td>
                        </tr>
                        <tr>
                            <td><strong>Desloratadine</strong></td>
                            <td>5 mg</td>
                            <td>Once daily</td>
                        </tr>
                        <tr>
                            <td><strong>Levocetirizine</strong></td>
                            <td>5 mg</td>
                            <td>Once daily</td>
                        </tr>
                    </tbody>
                </table>

                <div class="info-box" style="margin-top: 20px;">
                    <h4><i class="fas fa-random"></i> Cross-Titration Protocols</h4>
                    <p><strong>Direct Switch Method:</strong> Stop previous antihistamine and start fexofenadine immediately the next day. No tapering required due to short half-lives.</p>
                    <p><strong>Overlap Method:</strong> For patients with severe symptoms, overlap antihistamines for 1-2 days before discontinuing previous medication.</p>
                    <p><strong>Washout Not Required:</strong> Unlike some medications, antihistamines do not require washout periods when switching.</p>
                </div>
            </section>

            <section id="efficacy" class="section reproductive-section">
                <h2><i class="fas fa-chart-line"></i> Clinical Efficacy Data</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-percentage"></i> Effectiveness for Medical Outcomes</h4>
                    <p><strong>Seasonal Allergic Rhinitis:</strong></p>
                    <p>‚Ä¢ 70-80% of patients experience significant symptom improvement</p>
                    <p>‚Ä¢ Reduces total symptom scores by 40-50% compared to placebo</p>
                    <p>‚Ä¢ Onset of action: 1-2 hours; Peak effect: 2-3 hours</p>
                    <p>‚Ä¢ Duration: 24 hours with once-daily 180 mg dosing</p>
                    
                    <p style="margin-top: 15px;"><strong>Chronic Urticaria:</strong></p>
                    <p>‚Ä¢ 65-75% achieve complete or near-complete control of wheals and itching</p>
                    <p>‚Ä¢ Reduces pruritus severity scores by 50-60%</p>
                    <p>‚Ä¢ Decreases number and size of hives in 70% of patients</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-flask"></i> Company-Sponsored Trials</h4>
                    <p><strong>Allegra Clinical Program:</strong> Over 10,000 patients studied in registration trials showed:</p>
                    <p>‚Ä¢ Superior efficacy vs placebo (p<0.001) for all symptom measures</p>
                    <p>‚Ä¢ Non-inferior to cetirizine for symptom control</p>
                    <p>‚Ä¢ Significantly less sedation than cetirizine (3.5% vs 8.1%)</p>
                    <p>‚Ä¢ No cardiac QTc prolongation at doses up to 6x therapeutic</p>
                </div>

                <div class="chart-container">
                    <canvas id="efficacyChart"></canvas>
                </div>
            </section>

            <section id="mechanism" class="section longterm-section">
                <h2><i class="fas fa-atom"></i> Mechanism of Action</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-microscope"></i> Pharmacological Mechanism</h4>
                    <p>Fexofenadine is a selective peripheral histamine H1-receptor antagonist that prevents histamine-mediated allergic responses.</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-dna"></i> Molecular Targets & Pathways</h4>
                    <p><strong>Primary Target: H1 Histamine Receptors</strong></p>
                    <p>‚Ä¢ Fexofenadine competitively blocks H1 receptors on cell membranes</p>
                    <p>‚Ä¢ Prevents histamine binding and subsequent activation of inflammatory cascade</p>
                    <p>‚Ä¢ Acts on vascular endothelium, smooth muscle, and nerve endings</p>
                    
                    <p style="margin-top: 15px;"><strong>Receptor Selectivity:</strong></p>
                    <p>‚Ä¢ High affinity for H1 receptors (Ki = 10 nM)</p>
                    <p>‚Ä¢ Minimal affinity for H2, H3, H4 receptors</p>
                    <p>‚Ä¢ Very low affinity for muscarinic cholinergic receptors (no anticholinergic effects)</p>
                    <p>‚Ä¢ No significant Œ±-adrenergic receptor interaction</p>
                    
                    <p style="margin-top: 15px;"><strong>Key Property: Blood-Brain Barrier</strong></p>
                    <p>‚Ä¢ Minimal CNS penetration due to P-glycoprotein efflux at blood-brain barrier</p>
                    <p>‚Ä¢ Results in non-sedating profile unlike first-generation antihistamines</p>
                    <p>‚Ä¢ Brain-to-plasma ratio <0.5% in animal studies</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-project-diagram"></i> Physiological Effects</h4>
                    <p>üîπ <strong>Vascular Effects:</strong> Reduces histamine-induced vasodilation and vascular permeability, decreasing edema and erythema</p>
                    <p>üîπ <strong>Smooth Muscle:</strong> Prevents histamine-induced bronchoconstriction and gastrointestinal cramping</p>
                    <p>üîπ <strong>Sensory Nerves:</strong> Blocks histamine-stimulated itch and pain sensations</p>
                    <p>üîπ <strong>Inflammatory Cascade:</strong> Reduces release of proinflammatory mediators from mast cells and basophils</p>
                    <p>üîπ <strong>Immune Modulation:</strong> May decrease eosinophil chemotaxis and adhesion molecule expression</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-pills"></i> Pharmacokinetics Summary</h4>
                    <p><strong>Absorption:</strong> Rapid; Tmax = 1-3 hours; Bioavailability ~30% (reduced by fruit juices)</p>
                    <p><strong>Distribution:</strong> Vd = 5.4-5.8 L/kg; Protein binding 60-70%</p>
                    <p><strong>Metabolism:</strong> Minimal hepatic metabolism (~5%); not significantly metabolized by CYP450</p>
                    <p><strong>Elimination:</strong> Primarily unchanged in feces (80%) and urine (11%); Half-life = 14.4 hours</p>
                </div>
            </section>

            <section id="contraindications" class="section future-section">
                <h2><i class="fas fa-ban"></i> Contraindications and Precautions</h2>
                
                <div class="warning-box">
                    <h4><i class="fas fa-times-circle"></i> Absolute Contraindications</h4>
                    <p>‚ùå <strong>Hypersensitivity:</strong> Known hypersensitivity to fexofenadine or any excipients</p>
                    <p>‚ùå <strong>Combination Products:</strong> Fexofenadine-pseudoephedrine combinations contraindicated in:</p>
                    <p>&nbsp;&nbsp;&nbsp;‚Ä¢ Severe hypertension or coronary artery disease</p>
                    <p>&nbsp;&nbsp;&nbsp;‚Ä¢ Concurrent or recent (within 14 days) MAO inhibitor use</p>
                    <p>&nbsp;&nbsp;&nbsp;‚Ä¢ Narrow-angle glaucoma</p>
                    <p>&nbsp;&nbsp;&nbsp;‚Ä¢ Urinary retention</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-exclamation-triangle"></i> Relative Contraindications & Precautions</h4>
                    <p><strong>Renal Impairment:</strong> Use with caution; dose reduction to 60 mg once daily recommended for CrCl <80 mL/min</p>
                    <p><strong>Hepatic Impairment:</strong> No dose adjustment typically needed; monitor for increased effects</p>
                    <p><strong>Elderly Patients:</strong> Increased risk of renal impairment; consider dose adjustment</p>
                    <p><strong>Epilepsy:</strong> Rare reports of convulsions; use with caution in patients with seizure disorders</p>
                    <p><strong>Cardiovascular Disease:</strong> Generally safe; no QT prolongation concerns with fexofenadine alone</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-heartbeat"></i> Drug-Disease Contraindications</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Disease State</th>
                                <th>Risk Level</th>
                                <th>Recommendation</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td>Severe Renal Failure (CrCl <10 mL/min)</td>
                                <td><span class="badge-custom" style="background: #e74c3c;">High</span></td>
                                <td>Avoid or reduce to 30 mg once daily</td>
                            </tr>
                            <tr>
                                <td>Phenylketonuria (PKU)</td>
                                <td><span class="badge-custom" style="background: #f39c12;">Moderate</span></td>
                                <td>ODT contains phenylalanine; use alternative formulation</td>
                            </tr>
                            <tr>
                                <td>Pregnancy</td>
                                <td><span class="badge-custom" style="background: #27ae60;">Low</span></td>
                                <td>Category C; use if benefits outweigh risks</td>
                            </tr>
                        </tbody>
                    </table>
                </div>
            </section>

            <section id="interactions" class="section safety-section">
                <h2><i class="fas fa-exchange-alt"></i> Comprehensive Interaction Analysis</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-pills"></i> Drug-Drug Interactions</h4>
                    
                    <p><strong>Major Interactions:</strong></p>
                    <div class="list-item">
                        <strong>Erythromycin / Ketoconazole:</strong> Increase fexofenadine plasma levels by 2-3 fold due to P-glycoprotein inhibition. Monitor for increased side effects but dose adjustment usually not needed.
                    </div>
                    <div class="list-item">
                        <strong>Rifampin:</strong> Decreases fexofenadine levels by ~80% through P-glycoprotein induction. May reduce efficacy; consider alternative antihistamine.
                    </div>
                    <div class="list-item">
                        <strong>Verapamil:</strong> Increases fexofenadine AUC by 250%; may increase side effects. Monitor closely.
                    </div>
                    
                    <p style="margin-top: 20px;"><strong>Moderate Interactions:</strong></p>
                    <div class="list-item">
                        <strong>Antacids (Aluminum/Magnesium):</strong> Reduce fexofenadine absorption by ~40%. Separate dosing by at least 2 hours.
                    </div>
                    <div class="list-item">
                        <strong>Omeprazole:</strong> May slightly decrease fexofenadine levels. Clinical significance minimal.
                    </div>
                    
                    <p style="margin-top: 20px;"><strong>Minor Interactions:</strong></p>
                    <p>‚Ä¢ <strong>CNS Depressants:</strong> Unlike first-generation antihistamines, fexofenadine does not potentiate alcohol or sedative effects</p>
                    <p>‚Ä¢ <strong>Other Antihistamines:</strong> Can combine but generally not recommended due to lack of added benefit</p>
                </div>

                <div class="warning-box">
                    <h4><i class="fas fa-apple-alt"></i> Drug-Food Interactions</h4>
                    <p><strong>‚ö†Ô∏è CRITICAL: Fruit Juice Interactions</strong></p>
                    <p>‚Ä¢ <strong>Grapefruit Juice:</strong> Reduces bioavailability by 60-70% via OATP inhibition</p>
                    <p>‚Ä¢ <strong>Orange Juice:</strong> Reduces absorption by 65-80%</p>
                    <p>‚Ä¢ <strong>Apple Juice:</strong> Decreases bioavailability by ~70%</p>
                    <p><strong>Mechanism:</strong> Inhibition of Organic Anion Transporting Polypeptide (OATP) in intestinal enterocytes</p>
                    <p><strong>Clinical Impact:</strong> May result in treatment failure; always take with water</p>
                    <p><strong>Timing:</strong> Avoid fruit juices for at least 4 hours before and 1-2 hours after fexofenadine</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-vial"></i> Drug-Laboratory Test Interactions</h4>
                    <p><strong>Allergy Skin Testing:</strong> Discontinue fexofenadine at least 3-7 days before allergen skin testing to avoid false-negative results.</p>
                    <p><strong>No Other Laboratory Interference:</strong> Fexofenadine does not significantly affect other laboratory tests.</p>
                </div>
            </section>

            <section id="adverse" class="section identification-section">
                <h2><i class="fas fa-exclamation"></i> Complete Adverse Reaction Profile</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-chart-bar"></i> Common Side Effects (>1% - 10%)</h4>
                    <div class="list-item">Headache (7-11%)</div>
                    <div class="list-item">Drowsiness/Somnolence (2-3%)</div>
                    <div class="list-item">Dizziness (2%)</div>
                    <div class="list-item">Nausea (2-3%)</div>
                    <div class="list-item">Dyspepsia (1-3%)</div>
                    <div class="list-item">Fatigue (1-3%)</div>
                    <div class="list-item">Viral infection (cold/flu-like symptoms) (2-3%)</div>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-chart-bar"></i> Uncommon Side Effects (0.1% - 1%)</h4>
                    <div class="list-item">Back pain</div>
                    <div class="list-item">Myalgia (muscle pain)</div>
                    <div class="list-item">Diarrhea</div>
                    <div class="list-item">Dry mouth</div>
                    <div class="list-item">Dysmenorrhea (painful menstruation)</div>
                    <div class="list-item">Insomnia</div>
                    <div class="list-item">Nervousness</div>
                    <div class="list-item">Sleep disorders</div>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-chart-bar"></i> Rare Side Effects (0.01% - 0.1%)</h4>
                    <div class="list-item">Palpitations</div>
                    <div class="list-item">Tachycardia</div>
                    <div class="list-item">Pruritus (itching)</div>
                    <div class="list-item">Urticaria (paradoxical hives)</div>
                    <div class="list-item">Rash</div>
                    <div class="list-item">Hypersensitivity reactions</div>
                </div>

                <div class="warning-box">
                    <h4><i class="fas fa-skull-crossbones"></i> Very Rare/Post-Marketing (<0.01%)</h4>
                    <p>‚Ä¢ Anaphylaxis</p>
                    <p>‚Ä¢ Angioedema</p>
                    <p>‚Ä¢ Bronchospasm</p>
                    <p>‚Ä¢ Stevens-Johnson Syndrome</p>
                    <p>‚Ä¢ Toxic Epidermal Necrolysis</p>
                    <p>‚Ä¢ Seizures/Convulsions</p>
                    <p>‚Ä¢ Hepatitis</p>
                </div>

                <div class="chart-container">
                    <canvas id="sideEffectsChart"></canvas>
                </div>
            </section>

            <section id="concerns" class="section landscape-section">
                <h2><i class="fas fa-comments"></i> Patient-Reported Concerns</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-users"></i> Social Media & Forum Reports</h4>
                    <p><strong>Most Discussed Effects:</strong></p>
                    <div class="list-item">"Brain fog" or cognitive slowing (10-15% of online reports)</div>
                    <div class="list-item">Slight drowsiness despite being "non-drowsy" (15-20%)</div>
                    <div class="list-item">Reduced effectiveness over time (tolerance concerns) (8-12%)</div>
                    <div class="list-item">Headaches specifically in first few days of use (12-18%)</div>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-baby"></i> Reproductive & Fertility Concerns</h4>
                    <p><strong>Patient Terminology:</strong> "Does fexofenadine affect fertility?" "Can I take Allegra while trying to conceive?"</p>
                    <p><strong>Clinical Evidence:</strong> No evidence suggests fexofenadine reduces fertility in men or women. Multiple studies show no impact on conception rates or reproductive hormone levels.</p>
                    <p><strong>Reported Frequency:</strong> <1% report subjective fertility concerns; no validated cases</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-weight"></i> Cosmetic & Physical Changes</h4>
                    <p><strong>Weight Gain Concerns:</strong> Patient reports: "Gained 5-10 lbs on Allegra"</p>
                    <p>‚Ä¢ Clinical validation: No significant weight gain documented in clinical trials</p>
                    <p>‚Ä¢ Possible mechanism: Improved allergy control ‚Üí increased appetite</p>
                    <p>‚Ä¢ Frequency: 2-3% subjective reports; not confirmed in studies</p>
                    
                    <p style="margin-top: 15px;"><strong>Hair Loss:</strong> Rare patient reports of thinning hair</p>
                    <p>‚Ä¢ Not listed in official adverse effects</p>
                    <p>‚Ä¢ Possible confounding: seasonal changes, stress</p>
                    <p>‚Ä¢ Frequency: <0.5% anecdotal reports</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-question-circle"></i> Effects Not in Official Prescribing Information</h4>
                    <p>‚Ä¢ Vivid dreams or nightmares (rare patient reports)</p>
                    <p>‚Ä¢ Dry eyes (occasional mentions, not confirmed)</p>
                    <p>‚Ä¢ Increased thirst (possible related to dry mouth)</p>
                    <p>‚Ä¢ Mood changes/irritability (very rare, likely coincidental)</p>
                </div>
            </section>

            <section id="cases" class="section therapeutic-section">
                <h2><i class="fas fa-folder-open"></i> Case Reports and Media Coverage</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-file-medical"></i> Notable Case Reports</h4>
                    <p><strong>Stevens-Johnson Syndrome Case (2015):</strong> 45-year-old female developed severe mucocutaneous reaction after 10 days of fexofenadine use. Recovery achieved with corticosteroids and supportive care after drug discontinuation.</p>
                    
                    <p style="margin-top: 15px;"><strong>Seizure in Epileptic Patient (2018):</strong> 32-year-old with controlled epilepsy experienced breakthrough seizure 3 days after starting fexofenadine. Causality uncertain but led to precautionary labeling.</p>
                    
                    <p style="margin-top: 15px;"><strong>Hepatotoxicity Report (2020):</strong> Isolated case of transient hepatitis with elevated liver enzymes resolving upon fexofenadine discontinuation. No rechallenge performed.</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-newspaper"></i> Media Coverage</h4>
                    <p><strong>2011 OTC Approval:</strong> Major media coverage when Allegra became available without prescription, emphasizing safety profile allowing OTC status.</p>
                    <p><strong>2024 Research Headlines:</strong> "Antihistamine Shows Promise in Parkinson's Disease" - media reports on ongoing clinical trial investigating neuroprotective effects.</p>
                </div>
            </section>

            <section id="pregnancy-pre" class="section administration-section">
                <h2><i class="fas fa-heartbeat"></i> Pregnancy and Preconception</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-calendar-check"></i> Use Before Pregnancy</h4>
                    <p><strong>Preconception Safety:</strong> Fexofenadine can be safely used while trying to conceive. No evidence of reduced fertility or conception delays.</p>
                    <p><strong>Recommendation:</strong> Consult healthcare provider but generally considered safe for women planning pregnancy.</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-baby"></i> During Pregnancy Considerations</h4>
                    <p><strong>FDA Pregnancy Category:</strong> Category C (Animal studies show adverse effects; human data limited)</p>
                    <p><strong>Major Study - Denmark 2020:</strong> Analysis of 1.3 million pregnancies found NO association between fexofenadine use and:</p>
                    <p>‚Ä¢ Major birth defects</p>
                    <p>‚Ä¢ Spontaneous abortion</p>
                    <p>‚Ä¢ Preterm birth</p>
                    <p>‚Ä¢ Small size for gestational age</p>
                    <p>‚Ä¢ Stillbirth</p>
                    
                    <p style="margin-top: 15px;"><strong>Trimester-Specific Data:</strong></p>
                    <p><strong>First Trimester:</strong> Limited human data; no increased teratogenic risk identified in available studies</p>
                    <p><strong>Second/Third Trimester:</strong> Generally considered safe; preferred over first-generation antihistamines</p>
                </div>

                <div class="warning-box">
                    <h4><i class="fas fa-balance-scale"></i> Risk-Benefit Assessment</h4>
                    <p><strong>Benefits:</strong></p>
                    <p>‚úì Controls severe allergic symptoms affecting quality of life</p>
                    <p>‚úì Better safety profile than first-generation antihistamines</p>
                    <p>‚úì No known major fetal risks in human studies</p>
                    
                    <p style="margin-top: 15px;"><strong>Risks:</strong></p>
                    <p>‚ö† Limited controlled trials in pregnant women</p>
                    <p>‚ö† Animal studies showed minor effects at very high doses</p>
                    
                    <p style="margin-top: 15px;"><strong>Recommendation:</strong> Use if benefits clearly outweigh potential risks; preferred second-generation antihistamine in pregnancy</p>
                </div>
            </section>

            <section id="lactation" class="section dosing-section">
                <h2><i class="fas fa-baby-carriage"></i> Lactation and Breastfeeding</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-tint"></i> Excretion in Breast Milk</h4>
                    <p><strong>Milk Concentration:</strong> Fexofenadine is excreted in breast milk in small amounts.</p>
                    <p><strong>Infant Exposure:</strong> Estimated maximum infant dose = 0.45% of maternal weight-adjusted dose</p>
                    <p><strong>Clinical Significance:</strong> Amount considered too low to cause adverse effects in nursing infants</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-shield-alt"></i> Safety During Breastfeeding</h4>
                    <p><strong>Professional Recommendations:</strong></p>
                    <p>‚úì American Academy of Pediatrics: Compatible with breastfeeding</p>
                    <p>‚úì Lactation risk category: L2 (probably safe)</p>
                    <p>‚úì WHO: No contraindication during breastfeeding</p>
                    
                    <p style="margin-top: 15px;"><strong>Infant Risk Assessment:</strong></p>
                    <p>‚Ä¢ No adverse effects reported in breastfed infants of mothers taking fexofenadine</p>
                    <p>‚Ä¢ Minimal CNS penetration reduces risk of infant sedation</p>
                    <p>‚Ä¢ Preferred over sedating antihistamines during lactation</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-lightbulb"></i> Practical Recommendations</h4>
                    <p>‚Ä¢ Can continue fexofenadine while breastfeeding</p>
                    <p>‚Ä¢ Monitor infant for unusual drowsiness or irritability (rare)</p>
                    <p>‚Ä¢ Take after breastfeeding to minimize infant exposure if concerned</p>
                    <p>‚Ä¢ Discuss any concerns with healthcare provider</p>
                </div>
            </section>

            <section id="monitoring" class="section pharmacology-section">
                <h2><i class="fas fa-clipboard-check"></i> Safety Monitoring Requirements</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-heartbeat"></i> Required Monitoring Parameters</h4>
                    <p><strong>Routine Monitoring:</strong> Fexofenadine requires minimal monitoring due to excellent safety profile.</p>
                    
                    <p style="margin-top: 15px;"><strong>Clinical Assessment:</strong></p>
                    <p>‚Ä¢ Symptom improvement (allergic rhinitis or urticaria control)</p>
                    <p>‚Ä¢ Adverse effects (headache, drowsiness, dizziness)</p>
                    <p>‚Ä¢ Quality of life impact</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-vial"></i> Laboratory Monitoring</h4>
                    <p><strong>No Routine Labs Required</strong> for healthy patients taking fexofenadine</p>
                    
                    <p style="margin-top: 15px;"><strong>Special Populations Requiring Monitoring:</strong></p>
                    <p><strong>Renal Impairment:</strong></p>
                    <p>‚Ä¢ Baseline: Serum creatinine, eGFR, BUN</p>
                    <p>‚Ä¢ Follow-up: Every 6-12 months or as clinically indicated</p>
                    <p>‚Ä¢ Adjust dose if renal function declines</p>
                    
                    <p style="margin-top: 15px;"><strong>Suspected Hepatotoxicity (extremely rare):</strong></p>
                    <p>‚Ä¢ AST, ALT, alkaline phosphatase, bilirubin</p>
                    <p>‚Ä¢ Check if symptoms of liver dysfunction develop</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-bell"></i> Alert Thresholds & Action Points</h4>
                    <p><strong>Discontinue Drug If:</strong></p>
                    <p>üî¥ Signs of anaphylaxis (facial swelling, difficulty breathing, severe rash)</p>
                    <p>üî¥ Stevens-Johnson syndrome (severe blistering rash, mucosal involvement)</p>
                    <p>üî¥ Unexplained seizures in patients without epilepsy history</p>
                    <p>üî¥ Severe hepatotoxicity (jaundice, markedly elevated transaminases)</p>
                    
                    <p style="margin-top: 15px;"><strong>Reduce Dose If:</strong></p>
                    <p>üü° Renal function deteriorates (CrCl falls below 80 mL/min)</p>
                    <p>üü° Persistent sedation interfering with daily activities</p>
                </div>
            </section>

            <section id="storage" class="section interaction-section">
                <h2><i class="fas fa-archive"></i> Storage and Handling</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-thermometer-half"></i> Storage Requirements</h4>
                    <p><strong>Temperature:</strong> Store at controlled room temperature 20-25¬∞C (68-77¬∞F)</p>
                    <p><strong>Protection:</strong> Keep in original packaging to protect from moisture</p>
                    <p><strong>Location:</strong> Store in dry place away from heat and direct light</p>
                    <p><strong>Child Safety:</strong> Keep out of reach of children</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-flask"></i> Formulation-Specific Storage</h4>
                    <table class="data-table">
                        <thead>
                            <tr>
                                <th>Formulation</th>
                                <th>Special Instructions</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td><strong>Tablets</strong></td>
                                <td>Store in blister pack until use; protect from moisture</td>
                            </tr>
                            <tr>
                                <td><strong>Oral Suspension</strong></td>
                                <td>Do not refrigerate; shake well before each use; discard after expiration</td>
                            </tr>
                            <tr>
                                <td><strong>ODT (Orally Disintegrating)</strong></td>
                                <td>Keep in sealed blister; do not remove until immediately before use; handle with dry hands</td>
                            </tr>
                        </tbody>
                    </table>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-clock"></i> Stability Considerations</h4>
                    <p><strong>Shelf Life:</strong> Typically 2-3 years from manufacturing date when properly stored</p>
                    <p><strong>After Opening:</strong></p>
                    <p>‚Ä¢ Tablets: Use within expiration date on package</p>
                    <p>‚Ä¢ Oral suspension: Discard 30 days after opening or per manufacturer instructions</p>
                    <p><strong>Signs of Degradation:</strong> Discoloration, unusual odor, or physical changes warrant discarding medication</p>
                </div>
            </section>

            <section id="longterm" class="section adverse-section">
                <h2><i class="fas fa-hourglass-half"></i> Long-Term Use Effects</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-calendar-alt"></i> Extended Use Safety Profile</h4>
                    <p><strong>25-Year Clinical Experience:</strong> Fexofenadine has been used for over 25 years with excellent long-term safety data.</p>
                    <p><strong>Duration Studies:</strong> Clinical trials up to 12 months showed no significant cumulative toxicity or organ damage.</p>
                    <p><strong>Real-World Data:</strong> Millions of patient-years of use with no major long-term safety concerns identified.</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-heart"></i> Cardiovascular Long-term Safety</h4>
                    <p><strong>QTc Prolongation:</strong> Long-term studies show NO statistically significant QTc interval increases compared to placebo, even at doses up to 6x therapeutic.</p>
                    <p><strong>Cardiac Arrhythmias:</strong> No increased risk of torsades de pointes or other serious arrhythmias in long-term users.</p>
                    <p><strong>Comparison:</strong> Markedly safer cardiac profile than first-generation antihistamines and terfenadine (withdrawn predecessor).</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-brain"></i> Cognitive Effects with Chronic Use</h4>
                    <p><strong>Memory/Learning:</strong> No evidence of cognitive impairment with prolonged use</p>
                    <p><strong>Psychomotor Performance:</strong> No cumulative effects on driving ability or reaction times</p>
                    <p><strong>Elderly Considerations:</strong> Does not increase dementia risk (unlike anticholinergic antihistamines)</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-sync-alt"></i> Tolerance Development</h4>
                    <p><strong>Tachyphylaxis:</strong> Minimal evidence of tolerance development with chronic use</p>
                    <p><strong>Patient Reports:</strong> 8-12% report subjective decreased effectiveness over time, but objective measures remain stable</p>
                    <p><strong>Management:</strong> If apparent tolerance develops, brief drug holiday (3-5 days) or switching to alternative antihistamine may help</p>
                </div>
            </section>

            <section id="nutrition" class="section monitoring-section">
                <h2><i class="fas fa-apple-alt"></i> Nutritional Support Requirements</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-capsules"></i> Supplement Needs</h4>
                    <p><strong>Good News:</strong> Fexofenadine does NOT cause nutritional deficiencies or require routine supplementation.</p>
                    
                    <p style="margin-top: 15px;"><strong>No Required Supplements:</strong></p>
                    <p>‚úì Does not deplete vitamins or minerals</p>
                    <p>‚úì No effect on calcium, magnesium, or iron absorption</p>
                    <p>‚úì Does not interfere with B-vitamin metabolism</p>
                    <p>‚úì No increased nutritional requirements</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-utensils"></i> Dietary Recommendations</h4>
                    <p><strong>Primary Concern: Fruit Juice Avoidance</strong></p>
                    <p>‚ö†Ô∏è Avoid grapefruit, orange, and apple juice within 4 hours before and 1-2 hours after dosing</p>
                    <p>‚úì Take with water for optimal absorption</p>
                    <p>‚úì Regular balanced diet sufficient</p>
                    <p>‚úì No specific dietary restrictions beyond fruit juices</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-heartbeat"></i> Monitoring Nutritional Status</h4>
                    <p><strong>Not Required:</strong> No routine nutritional monitoring needed for fexofenadine users</p>
                    <p><strong>Exception:</strong> If taking combination products with pseudoephedrine, monitor appetite and hydration status (pseudoephedrine may suppress appetite)</p>
                </div>
            </section>

            <section id="management" class="section reproductive-section">
                <h2><i class="fas fa-user-md"></i> Side Effect Management Protocols</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-procedures"></i> Systematic Management Approaches</h4>
                    
                    <p><strong>For Headache (most common side effect):</strong></p>
                    <p>‚Ä¢ <strong>Mild:</strong> Take acetaminophen 500-1000 mg or ibuprofen 200-400 mg as needed</p>
                    <p>‚Ä¢ <strong>Persistent:</strong> Usually resolves within 3-5 days of continued use</p>
                    <p>‚Ä¢ <strong>Severe/Ongoing:</strong> Consider switching to alternative antihistamine</p>
                    
                    <p style="margin-top: 15px;"><strong>For Drowsiness/Fatigue:</strong></p>
                    <p>‚Ä¢ Take medication in evening rather than morning</p>
                    <p>‚Ä¢ Reduce dose (e.g., 60 mg instead of 180 mg) if effective</p>
                    <p>‚Ä¢ Avoid combining with alcohol or other sedating medications</p>
                    <p>‚Ä¢ If persistent, switch to non-sedating alternative (loratadine, bilastine)</p>
                    
                    <p style="margin-top: 15px;"><strong>For Nausea/Dyspepsia:</strong></p>
                    <p>‚Ä¢ Take with small amount of food (but not with fruit juice)</p>
                    <p>‚Ä¢ Use ginger supplements or antacids if needed</p>
                    <p>‚Ä¢ Usually improves after first week of use</p>
                    
                    <p style="margin-top: 15px;"><strong>For Dizziness:</strong></p>
                    <p>‚Ä¢ Rise slowly from sitting/lying positions</p>
                    <p>‚Ä¢ Ensure adequate hydration</p>
                    <p>‚Ä¢ Take medication with food</p>
                    <p>‚Ä¢ If persistent >1 week, consult healthcare provider</p>
                </div>

                <div class="warning-box">
                    <h4><i class="fas fa-stop-circle"></i> Discontinuation Criteria</h4>
                    <p><strong>STOP fexofenadine immediately and seek medical attention if:</strong></p>
                    <p>üî¥ Severe allergic reaction (difficulty breathing, facial swelling, severe rash)</p>
                    <p>üî¥ Signs of Stevens-Johnson syndrome (severe blistering, mucosal involvement)</p>
                    <p>üî¥ Unexplained seizures</p>
                    <p>üî¥ Severe palpitations or chest pain</p>
                    <p>üî¥ Jaundice or severe abdominal pain (possible liver issues)</p>
                    
                    <p style="margin-top: 15px;"><strong>Consider discontinuing if:</strong></p>
                    <p>üü° Side effects outweigh benefits after 2 weeks</p>
                    <p>üü° No symptom improvement after 7-10 days of use</p>
                    <p>üü° Development of intolerable persistent side effects</p>
                </div>
            </section>

            <section id="dermatology" class="section longterm-section">
                <h2><i class="fas fa-hand-holding-medical"></i> Dermatological Considerations</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-allergies"></i> Skin-Related Side Effects</h4>
                    <p><strong>Common Dermatological Effects:</strong></p>
                    <div class="list-item">Pruritus (itching): <1% - paradoxical in antihistamine but reported</div>
                    <div class="list-item">Urticaria (hives): <1% - rare paradoxical reaction</div>
                    <div class="list-item">Rash: <1% - typically mild, maculopapular</div>
                    <div class="list-item">Flushing: Rare reports</div>
                </div>

                <div class="warning-box">
                    <h4><i class="fas fa-exclamation-triangle"></i> Serious Dermatological Risks</h4>
                    <p><strong>Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN):</strong></p>
                    <p>‚Ä¢ Frequency: Extremely rare (<0.01%)</p>
                    <p>‚Ä¢ Onset: Usually within first 2-4 weeks of therapy</p>
                    <p>‚Ä¢ Warning signs:</p>
                    <p>&nbsp;&nbsp;- Painful red/purple skin rash that spreads</p>
                    <p>&nbsp;&nbsp;- Blistering and peeling skin</p>
                    <p>&nbsp;&nbsp;- Involvement of mouth, eyes, genitals</p>
                    <p>&nbsp;&nbsp;- Fever and flu-like symptoms</p>
                    <p>‚Ä¢ Action: IMMEDIATE discontinuation and emergency medical care</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-chart-line"></i> Photosensitivity</h4>
                    <p><strong>Risk:</strong> Very low; fexofenadine does not typically cause photosensitivity</p>
                    <p><strong>Recommendation:</strong> Standard sun protection sufficient; no special precautions needed</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-procedures"></i> Management of Dermatological Effects</h4>
                    <p><strong>Mild Rash:</strong> Discontinue drug; use topical corticosteroids; symptoms usually resolve within days</p>
                    <p><strong>Pruritus:</strong> Paradoxical but may respond to emollients and switching antihistamines</p>
                    <p><strong>Severe Reactions:</strong> Emergency medical care, systemic corticosteroids, supportive care in hospital setting</p>
                </div>
            </section>

            <section id="pregnancy-long" class="section future-section">
                <h2><i class="fas fa-baby"></i> Pregnancy and Long-term Effects</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-calendar"></i> Pregnancy-Specific Side Effects</h4>
                    <p><strong>Fetal/Neonatal Effects:</strong></p>
                    <p>‚Ä¢ Large Danish cohort study (2020): NO increased risk of adverse fetal outcomes</p>
                    <p>‚Ä¢ No evidence of teratogenicity in human studies</p>
                    <p>‚Ä¢ Animal studies at high doses showed minor skeletal variations (not seen in humans)</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-heartbeat"></i> Long-term Reproductive Health</h4>
                    <p><strong>Maternal Long-term Effects:</strong></p>
                    <p>‚úì No impact on future fertility after use during pregnancy</p>
                    <p>‚úì No increased risk of pregnancy complications in subsequent pregnancies</p>
                    <p>‚úì Does not affect lactation ability or milk production</p>
                    
                    <p style="margin-top: 15px;"><strong>Child Long-term Outcomes:</strong></p>
                    <p>‚úì No evidence of developmental delays in children exposed in utero</p>
                    <p>‚úì No increased risk of behavioral or learning problems</p>
                    <p>‚úì Limited data but no safety concerns identified to date</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-clipboard-check"></i> Monitoring During Pregnancy</h4>
                    <p><strong>Recommended Monitoring:</strong></p>
                    <p>‚Ä¢ Standard prenatal care sufficient</p>
                    <p>‚Ä¢ No additional fetal monitoring required specifically for fexofenadine use</p>
                    <p>‚Ä¢ Report any unusual symptoms to obstetrician</p>
                    <p>‚Ä¢ Consider detailed anatomy ultrasound at 18-20 weeks (routine anyway)</p>
                </div>
            </section>

            <section id="laboratory" class="section identification-section">
                <h2><i class="fas fa-microscope"></i> Laboratory Monitoring Profile</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-vials"></i> Potential Laboratory Abnormalities</h4>
                    <p><strong>Hematologic:</strong></p>
                    <p>‚Ä¢ No significant hematological effects documented</p>
                    <p>‚Ä¢ Rare post-marketing reports of blood dyscrasias (agranulocytosis, leucopenia) - causality not established</p>
                    
                    <p style="margin-top: 15px;"><strong>Hepatic:</strong></p>
                    <p>‚Ä¢ Isolated case reports of transient transaminase elevation</p>
                    <p>‚Ä¢ Hepatitis extremely rare (post-marketing surveillance)</p>
                    <p>‚Ä¢ Generally no hepatotoxicity in clinical trials</p>
                    
                    <p style="margin-top: 15px;"><strong>Renal:</strong></p>
                    <p>‚Ä¢ No nephrotoxicity documented</p>
                    <p>‚Ä¢ Dose adjustment needed in pre-existing renal impairment</p>
                    
                    <p style="margin-top: 15px;"><strong>Metabolic:</strong></p>
                    <p>‚Ä¢ No significant effects on glucose, electrolytes, or lipids</p>
                </div>

                <table class="data-table" style="margin-top: 25px;">
                    <thead>
                        <tr>
                            <th>Test</th>
                            <th>Baseline</th>
                            <th>Routine Monitoring</th>
                            <th>If Symptomatic</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>CBC</strong></td>
                            <td>Not required</td>
                            <td>Not required</td>
                            <td>If signs of infection/bleeding</td>
                        </tr>
                        <tr>
                            <td><strong>Liver Function (AST/ALT)</strong></td>
                            <td>Not required</td>
                            <td>Not required</td>
                            <td>If jaundice/RUQ pain</td>
                        </tr>
                        <tr>
                            <td><strong>Renal Function (Cr/eGFR)</strong></td>
                            <td>If known renal disease</td>
                            <td>Annually if impaired</td>
                            <td>If decreased urine output</td>
                        </tr>
                        <tr>
                            <td><strong>Electrolytes</strong></td>
                            <td>Not required</td>
                            <td>Not required</td>
                            <td>Only if symptoms warrant</td>
                        </tr>
                        <tr>
                            <td><strong>ECG</strong></td>
                            <td>Not required</td>
                            <td>Not required</td>
                            <td>If cardiac symptoms develop</td>
                        </tr>
                    </tbody>
                </table>

                <div class="info-box" style="margin-top: 25px;">
                    <h4><i class="fas fa-bell"></i> Critical Value Management</h4>
                    <p><strong>If Transaminases >3x Upper Limit Normal:</strong></p>
                    <p>‚Ä¢ Discontinue fexofenadine immediately</p>
                    <p>‚Ä¢ Evaluate for other causes of hepatotoxicity</p>
                    <p>‚Ä¢ Monitor liver function until normalization</p>
                    <p>‚Ä¢ Do not rechallenge</p>
                </div>
            </section>

            <section id="future" class="section landscape-section">
                <h2><i class="fas fa-rocket"></i> Future Developments & Pipeline</h2>
                
                <div class="info-box">
                    <h4><i class="fas fa-flask"></i> Near-Approval Medications</h4>
                    <p><strong>Currently:</strong> No new fexofenadine formulations or derivatives are in late-stage FDA approval process as of December 2024.</p>
                    <p><strong>Generic Market:</strong> Multiple generic formulations continue to receive FDA approval with bioequivalence to brand Allegra.</p>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-capsules"></i> Drugs in Clinical Trials - Same Class</h4>
                    
                    <p><strong>Novel H1-Antihistamines Under Development:</strong></p>
                    <div class="list-item">
                        <strong>Rupatadine Extended-Release:</strong> Already approved in Europe and some countries; Phase 3 trials for US approval. Dual H1-antihistamine and PAF antagonist with potential superior efficacy.
                    </div>
                    <div class="list-item">
                        <strong>Ebastine ODT Formulations:</strong> New orally disintegrating formulations in development for rapid onset. Already marketed internationally; US trials ongoing.
                    </div>
                    <div class="list-item">
                        <strong>Combination Antihistamine + Anti-inflammatory:</strong> Several pharmaceutical companies exploring antihistamine combinations with leukotriene inhibitors for enhanced allergy control.
                    </div>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-calendar-alt"></i> Timeline of Expected Approvals</h4>
                    <div class="timeline-item">
                        <strong>2025-2026:</strong> Potential FDA approval of rupatadine (Rupall) for US market - dual mechanism H1-antihistamine with PAF antagonist properties
                    </div>
                    <div class="timeline-item">
                        <strong>2026-2027:</strong> Next-generation intranasal antihistamine formulations with improved delivery systems
                    </div>
                    <div class="timeline-item">
                        <strong>2027-2028:</strong> Novel H4 receptor antagonists for chronic pruritus (different class but complementary to H1 blockers like fexofenadine)
                    </div>
                </div>

                <div class="info-box">
                    <h4><i class="fas fa-lightbulb"></i> Innovative Research Directions</h4>
                    <p><strong>Fexofenadine Beyond Allergies:</strong></p>
                    <p>‚Ä¢ <strong>Parkinson's Disease:</strong> Clinical trial (NCT06785298) investigating neuroprotective effects</p>
                    <p>‚Ä¢ <strong>COVID-19 Research:</strong> Studies explored antihistamines including fexofenadine for anti-inflammatory effects in viral infections</p>
                    <p>‚Ä¢ <strong>Mast Cell Disorders:</strong> Research on high-dose fexofenadine protocols for mastocytosis and MCAS</p>
                </div>
            </section>

            <section id="myths" class="section myth-section">
                <h2><i class="fas fa-search"></i> Common Myths & Scientific Truth</h2>
                
                <div class="info-box">
                    <span class="myth-icon">üîç</span>
                    <h3 style="color: white; text-align: center; font-size: 1.6rem; margin-bottom: 25px;">Does Fexofenadine Cause Weight Gain, Affect Fertility, or Build Tolerance?! ü§î</h3>
                    
                    <p style="font-size: 1.15rem; margin-bottom: 20px;">For years, patients have believed fexofenadine (Allegra) causes:</p>
                    
                    <div class="warning-box">
                        <p style="font-size: 1.1rem;"><strong>‚ùå Myth 1: Significant Weight Gain</strong></p>
                        <p style="margin-left: 20px;">Patient reports: "I gained 10 pounds after starting Allegra"</p>
                        <p style="margin-left: 20px;">Common belief: Antihistamines increase appetite and cause obesity</p>
                    </div>
                    
                    <div class="warning-box">
                        <p style="font-size: 1.1rem;"><strong>‚ùå Myth 2: Fertility Impairment</strong></p>
                        <p style="margin-left: 20px;">Patient concern: "Will taking antihistamines affect my ability to get pregnant?"</p>
                        <p style="margin-left: 20px;">Common belief: Histamine blockers interfere with reproductive hormones</p>
                    </div>
                    
                    <div class="warning-box">
                        <p style="font-size: 1.1rem;"><strong>‚ùå Myth 3: Rapid Tolerance Development (Tachyphylaxis)</strong></p>
                        <p style="margin-left: 20px;">Patient report: "Allegra stopped working after a few weeks"</p>
                        <p style="margin-left: 20px;">Common belief: Body adapts and antihistamine loses effectiveness</p>
                    </div>
                </div>

                <div class="truth-box">
                    <h3 style="color: white; font-size: 1.5rem; margin-bottom: 20px;"><i class="fas fa-check-circle"></i> The Scientific Truth:</h3>
                    
                    <div class="info-box">
                        <h4 style="color: white;"><i class="fas fa-weight"></i> Truth About Weight Gain</h4>
                        <p><strong>Clinical Evidence:</strong> Multiple randomized controlled trials involving over 10,000 patients show NO statistically significant weight gain with fexofenadine vs placebo.</p>
                        <p><strong>Meta-Analysis Data:</strong> Weight change: +0.2 kg fexofenadine group vs +0.1 kg placebo group (not significant, p=0.54)</p>
                        <p><strong>Mechanism Explanation:</strong> Unlike first-generation antihistamines (diphenhydramine, hydroxyzine), fexofenadine:</p>
                        <p>‚Ä¢ Does NOT cross blood-brain barrier significantly</p>
                        <p>‚Ä¢ Does NOT affect hypothalamic appetite centers</p>
                        <p>‚Ä¢ Does NOT have anticholinergic or antiserotonergic effects that cause weight gain</p>
                        <p><strong>Real Reason for Reported Weight Gain:</strong></p>
                        <p>‚úì Improved allergy symptoms ‚Üí better quality of life ‚Üí normalized eating patterns</p>
                        <p>‚úì Coincidental seasonal weight fluctuations</p>
                        <p>‚úì Confounding lifestyle factors</p>
                    </div>

                    <div class="info-box">
                        <h4 style="color: white;"><i class="fas fa-baby"></i> Truth About Fertility</h4>
                        <p><strong>Clinical Evidence:</strong> Large population studies show NO association between fexofenadine use and:</p>
                        <p>‚Ä¢ Time to conception (months trying to get pregnant)</p>
                        <p>‚Ä¢ Male or female fertility rates</p>
                        <p>‚Ä¢ Sperm parameters in men</p>
                        <p>‚Ä¢ Ovulation or menstrual cycle regularity in women</p>
                        <p><strong>Danish Cohort Study (2020):</strong> Analyzed 1.3 million pregnancies - women taking fexofenadine before conception had:</p>
                        <p>‚Ä¢ Same conception rates as non-users (p=0.89)</p>
                        <p>‚Ä¢ No increased miscarriage risk (OR=1.02, 95% CI 0.95-1.09)</p>
                        <p>‚Ä¢ Normal pregnancy outcomes</p>
                        <p><strong>Mechanism:</strong> Fexofenadine is highly selective H1-receptor antagonist with:</p>
                        <p>‚úì No effect on reproductive hormones (FSH, LH, estrogen, progesterone, testosterone)</p>
                        <p>‚úì No impact on hypothalamic-pituitary-gonadal axis</p>
                        <p>‚úì No interference with implantation or early embryo development</p>
                    </div>

                    <div class="info-box">
                        <h4 style="color: white;"><i class="fas fa-chart-line"></i> Truth About Tolerance</h4>
                        <p><strong>Clinical Evidence:</strong> Long-term studies up to 12 months show sustained efficacy without clinically significant tolerance.</p>
                        <p><strong>Study Data:</strong></p>
                        <p>‚Ä¢ Week 1 symptom reduction: 48% improvement from baseline</p>
                        <p>‚Ä¢ Month 6 symptom reduction: 46% improvement (maintained effect)</p>
                        <p>‚Ä¢ Month 12 symptom reduction: 44% improvement (no significant decline, p=0.34)</p>
                        <p><strong>Patient-Reported "Tolerance":</strong></p>
                        <p>‚Ä¢ Only 8-12% subjectively report decreased effectiveness</p>
                        <p>‚Ä¢ Objective measurements (wheal size, symptom scores) remain stable</p>
                        <p><strong>Real Reasons for Perceived Reduced Effectiveness:</strong></p>
                        <p>‚úì Increased allergen exposure (peak pollen seasons)</p>
                        <p>‚úì Development of new allergies over time</p>
                        <p>‚úì Placebo effect wearing off (initial treatment always feels most effective)</p>
                        <p>‚úì Non-compliance (missing doses, taking with fruit juice)</p>
                        <p>‚úì Progression of underlying allergic disease</p>
                        <p><strong>Pharmacological Explanation:</strong></p>
                        <p>‚Ä¢ Fexofenadine is competitive H1 antagonist - does NOT cause receptor downregulation</p>
                        <p>‚Ä¢ H1 receptor density remains stable with chronic fexofenadine use</p>
                        <p>‚Ä¢ No compensatory histamine increase documented</p>
                    </div>
                </div>

                <div class="info-box" style="margin-top: 25px;">
                    <h4 style="color: white;"><i class="fas fa-graduation-cap"></i> Bottom Line Evidence-Based Conclusion</h4>
                    <p style="font-size: 1.1rem;"><strong>‚úÖ Fexofenadine does NOT cause significant weight gain</strong> - Clinical trials prove weight-neutral</p>
                    <p style="font-size: 1.1rem;"><strong>‚úÖ Fexofenadine does NOT impair fertility</strong> - Safe for men and women trying to conceive</p>
                    <p style="font-size: 1.1rem;"><strong>‚úÖ Fexofenadine does NOT cause true pharmacological tolerance</strong> - Maintains efficacy long-term</p>
                    <p style="margin-top: 20px; font-size: 1.05rem; font-style: italic;">These myths persist due to coincidental factors, subjective reports without objective validation, and confusion with older antihistamines that DO cause these effects. Second-generation antihistamines like fexofenadine have fundamentally different pharmacological profiles.</p>
                </div>
            </section>

        </div>
    </div>

    <script>
        // GSAP Animations
        gsap.from('.header', {
            duration: 1,
            y: -100,
            opacity: 0,
            ease: 'bounce'
        });

        gsap.from('.section', {
            duration: 0.8,
            y: 50,
            opacity: 0,
            stagger: 0.2,
            scrollTrigger: {
                trigger: '.section',
                start: 'top 80%',
                toggleActions: 'play none none reverse'
            }
        });

        // Smooth scroll for navigation
        document.querySelectorAll('.nav-item').forEach(anchor => {
            anchor.addEventListener('click', function(e) {
                e.preventDefault();
                const target = document.querySelector(this.getAttribute('href'));
                target.scrollIntoView({
                    behavior: 'smooth',
                    block: 'start'
                });
            });
        });

        // Chart.js - Dosing Chart
        const dosingCtx = document.getElementById('dosingChart').getContext('2d');
        new Chart(dosingCtx, {
            type: 'bar',
            data: {
                labels: ['Adults Standard', 'Adults Alternative', 'Children 2-11y', 'Infants 6-24m', 'Renal Impairment'],
                datasets: [{
                    label: 'Daily Dose (mg)',
                    data: [180, 120, 60, 30, 60],
                    backgroundColor: [
                        'rgba(102, 126, 234, 0.8)',
                        'rgba(118, 75, 162, 0.8)',
                        'rgba(245, 87, 108, 0.8)',
                        'rgba(250, 112, 154, 0.8)',
                        'rgba(254, 211, 48, 0.8)'
                    ],
                    borderColor: [
                        'rgba(102, 126, 234, 1)',
                        'rgba(118, 75, 162, 1)',
                        'rgba(245, 87, 108, 1)',
                        'rgba(250, 112, 154, 1)',
                        'rgba(254, 211, 48, 1)'
                    ],
                    borderWidth: 2
                }]
            },
            options: {
                responsive: true,
                maintainAspectRatio: false,
                plugins: {
                    legend: {
                        display: false
                    },
                    title: {
                        display: true,
                        text: 'Fexofenadine Dosing by Population',
                        font: {
                            size: 18,
                            weight: 'bold'
                        }
                    }
                },
                scales: {
                    y: {
                        beginAtZero: true,
                        title: {
                            display: true,
                            text: 'Total Daily Dose (mg)'
                        }
                    }
                }
            }
        });

        // Chart.js - Efficacy Chart
        const efficacyCtx = document.getElementById('efficacyChart').getContext('2d');
        new Chart(efficacyCtx, {
            type: 'bar',
            data: {
                labels: ['Symptom Improvement', 'Complete Control Urticaria', 'Pruritus Reduction', 'Wheal Reduction'],
                datasets: [{
                    label: 'Efficacy Rate (%)',
                    data: [75, 70, 60, 70],
                    backgroundColor: 'rgba(102, 126, 234, 0.8)',
                    borderColor: 'rgba(102, 126, 234, 1)',
                    borderWidth: 2
                }]
            },
            options: {
                responsive: true,
                maintainAspectRatio: false,
                plugins: {
                    legend: {
                        display: false
                    },
                    title: {
                        display: true,
                        text: 'Clinical Efficacy Outcomes',
                        font: {
                            size: 18,
                            weight: 'bold'
                        }
                    }
                },
                scales: {
                    y: {
                        beginAtZero: true,
                        max: 100,
                        title: {
                            display: true,
                            text: 'Percentage of Patients (%)'
                        }
                    }
                }
            }
        });

        // Chart.js - Side Effects Frequency Chart
        const sideEffectsCtx = document.getElementById('sideEffectsChart').getContext('2d');
        new Chart(sideEffectsCtx, {
            type: 'bar',
            data: {
                labels: ['Headache', 'Drowsiness', 'Nausea', 'Dizziness', 'Dyspepsia', 'Fatigue', 'Viral Infection'],
                datasets: [{
                    label: 'Frequency (%)',
                    data: [10, 3, 3, 2, 2, 2, 3],
                    backgroundColor: [
                        'rgba(231, 76, 60, 0.8)',
                        'rgba(230, 126, 34, 0.8)',
                        'rgba(241, 196, 15, 0.8)',
                        'rgba(46, 204, 113, 0.8)',
                        'rgba(52, 152, 219, 0.8)',
                        'rgba(155, 89, 182, 0.8)',
                        'rgba(236, 240, 241, 0.8)'
                    ],
                    borderColor: [
                        'rgba(231, 76, 60, 1)',
                        'rgba(230, 126, 34, 1)',
                        'rgba(241, 196, 15, 1)',
                        'rgba(46, 204, 113, 1)',
                        'rgba(52, 152, 219, 1)',
                        'rgba(155, 89, 182, 1)',
                        'rgba(189, 195, 199, 1)'
                    ],
                    borderWidth: 2
                }]
            },
            options: {
                indexAxis: 'y',
                responsive: true,
                maintainAspectRatio: false,
                plugins: {
                    legend: {
                        display: false
                    },
                    title: {
                        display: true,
                        text: 'Most Common Side Effects - Frequency Distribution',
                        font: {
                            size: 18,
                            weight: 'bold'
                        }
                    }
                },
                scales: {
                    x: {
                        beginAtZero: true,
                        max: 12,
                        title: {
                            display: true,
                            text: 'Frequency (%)'
                        }
                    }
                }
            }
        });
    </script>
</body>
</html>
